Trial Profile

A Clinical study to evaluate effectiveness of intravenous ketamine, in combination with internet-based cognitive behavioural therapy (iCBT), to rapidly reduce suicidality in persons with depression, when compared to iCBT alone

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 02 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Aug 2021 New trial record
28 Jul 2021 According to a Braxia Scientific media release, the study will be conducted at the Mississauga, Ontario and Toronto's University Health Network and Misericordia Community Hospital in Edmonton, Alberta.
28 Jul 2021 According to a Braxia Scientific media release, Dr. Roger Mclntyre and Dr. Josh Rosenblat recived $918,000 in funding from the Canadian Institutes of Health Research (CIHR), the Government of Canada's federal funding agency for health research for this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com